

American Society of Hematology Annual Meeting (ASH) 2015

Studies from US Oncology Research, The US Oncology Network
and McKesson Specialty Health Affiliated Investigators

Orange County Convention Center, Orlando, FL December 5-8, 2015

Oral Presentations			
Authors	Title	Session #	Date/Time
Jatin J. Shah, Ruben Niesvizky, Edward Stadtmauer, Robert M. Rifkin , James Berenson, Jesus G. Berdeja, Jeff P. Sharman , Roger Lyons , Zandra Klippel, Hansen Wong, Yu-Lin Chang, and Saad Usmani.	Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)	653 Abstract #378	Sunday, Dec. 6, Session: 4:30 PM to 6 PM Presentation: 5:45 PM
James Berenson, Alan Cartmell, Roger Lyons , Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph V. Boccia, Morton Coleman, Robert A. Moss, Robert M. Rifkin , Marco Schupp, Sandra Dixon, Ying Ou, Janet Anderl, and Jesus G. Berdeja.	Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)	653 Abstract #373	Sunday, Dec. 6, 4:30 PM to 6:30 PM
Michael R. Savona, Steven D. Gore, Kathryn S. Kolibaba , Stacey M. Ukrainskyj, Keshava Kumar, Qian Dong, Joel Hetzer, Barry Skikne, and Guillermo Garcia-Manero.	CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)	613 Abstract #452	Monday, Dec. 7, 7 AM to 8:30 AM

Bolded text: US Oncology Research affiliated investigator

Oral Presentations			
Authors	Title	Session #	Date/Time
Christopher A. Yasenchak , Andres Forero-Torres, Vivian Jean Mikao Cline-Burkhardt , Rodolfo E Bordoni, Dipti Patel-Donnelly , Patrick J. Flynn , Robert Chen, Abraham Fong, and Jonathan W. Friedberg.	Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study	624 Abstract #587	Monday, Dec. 7, 10:30 AM to 12 PM
Jonathan J Keats, Gil Speyer, Legendre Christophe, Christofferson Austin, Kristi Stephenson, Ahmet Kurdoglu, Megan Russell, Aldrich Jessica, Cuyugan Lori, Jonathan Adkins, Jackie McDonald, Adrienne Helland, Alex Blanski, Meghan Hodges, Dan Rohrer, Sundar Jagannath, David S Siegel, Ravi Vij, Gregory Orloff, Todd Zimmerman, Ruben Niesvizky, Darla Liles, Joseph W. Fay, Jeffrey L. Wolf, Robert M. Rifkin , Norma C Gutierrez, The MMRF CoMMpass Network, Jen Toups, Mary Derome, Winnie Liang, Seunchan Kim, Daniel Auclair, Pamela G. Kidd, Scott Jewell, John David Carpen, and Sagar Lonial.	Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study	651 Abstract #722	Monday, Dec. 7, 3:00 PM to 4:30 PM
Gilles A. Salles, Thomas E. Boyd , Franck Morschhauser, Clemens-Martin Wendtner, Michael Hallek, Barbara F. Eichhorst, Mark Kozloff, Guillaume Cartron, Yan Li, James Hilger, Mehrdad Mobasher, and Stephan Stilgenbauer.	Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia	642 Abstract #829	Monday, Dec. 7, 4:30 PM to 6 PM
John P. Leonard, Kathryn Kolibaba , James A. Reeves, Anil Tulpule, Ian W. Flinn, Tatjana Kolevska, Robert Robles, Christopher Flowers, Robert Collins, Nicholas J. DiBella , Steven W. Papish, Parameswaran Venugopal, Andrew Horodner, Amir Tabatabai, Julio Hajdenberg, George Mulligan, Rachel Neuwirth, Kaveri Suryanarayan, Dixie-Lee Esseltine, and Sven de Vos.	Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)	623 Abstract #811	Monday, Dec. 7, 4:30 PM to 6 PM
Christopher A. Yasenchak , Ahmad Halwani, Ranjana Advani, Stephen Ansell, Lihua Elizabeth Budde, John M. Burke , Charles M. Farber, Beata Holkova, Luis E. Fayad, Kathryn S. Kolibaba , Mark Knapp, Martha Li, Thomas J. Manley, Dipti Patel-Donnelly , Mahesh Seetharam , Habte A. Yimer , and Nancy L Bartlett.	Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study	623 Abstract #814	Monday, Dec. 7, 4:30 PM to 6 PM

Bolded text: US Oncology Research affiliated investigator

Poster Presentations			
Authors	Title	Session #	Date/Time
Jeff P. Sharman , Andrei R. Shustov, Mitchell R. Smith, Thomas E. Boyd , Christopher Hagenstad, Kathryn S. Kolibaba , Steve Abella, Jing He, Clarence Eng, Jing Hu, Anita Reddy, Siddhartha Mitra, Christopher A. Yasenckak , and Farrukh T. Awan.	Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling	642 Abstract #1744	Saturday, Dec. 5, 5:30 PM to 7:30 PM
Jeff P. Sharman , Leonard M. Klein , Michael Boxer , Kathryn S. Kolibaba , Steve Abella, Clarence Eng, Jing He, Jing Hu, and Christopher A. Yasenckak .	Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL)	624 Abstract #1545	Saturday, Dec. 5, 5:30 PM to 7:30 PM
Robert M. Rifkin , Eileen Fonseca, Yaozhu J. Chen, Patricia S. Fox, James E. Browning, and Ze Cong.	Carfilzomib Dosing Patterns and Survival in Patients with Relapsed and Refractory Multiple Myeloma: An Analysis from US Community Oncology Practices	902 Abstract #2084	Saturday, Dec. 5, 5:30 PM to 7:30 PM
Nancy L. Bartlett, Andy I Chen, Kathryn S. Kolibaba , Thierry Lamy, Surai Jones, Jamie Hirata, and Jeff P. Sharman .	Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation	624 Abstract #2726	Sunday, Dec. 6, 6 PM to 8 PM
Jennifer R. Brown, Bruce D. Cheson, Richard R. Furman, Paolo Ghia, Michael Hallek, Peter Hillmen, Susan O'Brien, Jeff P. Sharman , Ronald L. Dubowy, Barbara Velasco, Christopher C. Waldapfel, and Andrew D. Zelenetz.	Patterns of Lymphocytosis in CLL/SLL Patients Treated with Idelalisib	642 Abstract #2952	Sunday, Dec. 6, 6 PM to 8 PM
Nathan Fowler, Thomas E Boyd , Jeff P. Sharman , Sonali M. Smith, Fong Clow, Alvina D. Chu, and Ranjana H Advani.	Long-Term Follow-up and Analysis of Dose Groups with Ibrutinib in Relapsed Follicular Lymphoma	623 Abstract #2706	Sunday, Dec. 6, 6 PM to 8 PM
Kathryn Kolibaba , John M. Burke , Heather D. Brooks , Daruka Mahadevan, Jason Melear , Charles M. Farber, Suzanne R. Fanning , Marshall T. Schreeder, Ralph V. Boccia, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, and Jeff P. Sharman .	Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial	624 Abstract #3980	Monday, Dec. 7, 6 PM to 8 PM
Jatin J. Shah, Rafat Abonour, Mohit Narang , Jayesh Mehta, Howard R. Terebelo, Cristina J. Gasparetto, Kathleen Toomey, James W. Hardin, Shankar Srinivasan, Gail Larkins, Yasir Nagarwala, and Robert M. Rifkin .	Clinical Outcomes of Patients with Newly Diagnosed Multiple Myeloma Receiving Triplet Therapy in the Connect MM® Disease Registry	653 Abstract #4229	Monday, Dec. 7, 6 PM to 8 PM
Jeff P. Sharman , Leonard M. Klein , Michael Boxer , Kathryn S. Kolibaba , Steve Abella, Julie Di Paolo, Clarence Eng, Jing Hu, Jing He, Anita Reddy, and Christopher A. Yasenckak .	Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)	642 Abstract #4152	Monday, Dec. 7, 6 PM to 8 PM

Bolded text: US Oncology Research affiliated investigator

Poster Presentations			
Authors	Title	Session #	Date/Time
Anthony Mato, Chadi Nabhan, Christopher Flowers, Neil E. Kay, Thomas J. Kipps, David L. Grinblatt, Nicole Lamanna, Mark Kozloff, Kristen Sullivan, E. Dawn Flick, Pavel Kiselev, Shriya Bhushan, Arlene S. Swern, and Jeff P. Sharman.	Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry	902 Abstract #4483	Monday, Dec. 7, 6 PM to 8 PM
Susan O'Brien, Samantha Jaglowski, John C. Byrd, Rajat Bannerji, Kristie Blum, Christopher P. Fox, Richard R. Furman, Peter Hillmen, Thomas J. Kipps, Marco Montillo, Jeff P. Sharman, Sam Suzuki, Danelle James, Alvina D. Chu, and Steven Coutre.	Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL	642 Abstract #4153	Monday, Dec. 7, 6 PM to 8 PM
Anthony Mato, Chadi Nabhan, Christopher Flowers, Neil E. Kay, Thomas J. Kipps, David L. Grinblatt, Nicole Lamanna, Mark Kozloff, Kristen Sullivan, E. Dawn Flick, Pavel Kiselev, Shriya Bhushan, Arlene S. Swern, and Jeff P. Sharman.	Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry	902 Abstract #3284	Monday, Dec. 7, 6 PM to 8 PM

Bolded text: US Oncology Research affiliated investigator

Learn More Today

To learn more about US Oncology Research, please contact us.

For Pharmaceutical & Biotech customers:

call 866.951.2774, email us at USOncologyResearch@mckesson.com, or visit www.MckessonSpecialtyHealth.com/PharmaBiotech

For Providers:

call 800.482.6700, email us at msh.providers@mckesson.com, or visit www.usoncology.com